Researchers published in Nature Communications (2026) report a Granzyme B-mimetic nanozyme packaged in a targeted nanovesicle that selectively induces cancer-cell death. The team describes engineering a catalytic nanomaterial that mimics granzyme B’s proteolytic activity and concentrates at tumors via ligand-directed delivery. The paper details preclinical efficacy and mechanistic assays showing tumor-cell apoptosis after vesicle uptake; authors frame the approach as a platform for delivering proteolytic cytotoxicity without live immune cells. Granzyme B is a serine protease used by cytotoxic T and NK cells to trigger apoptosis; the nanozyme reproduces that biochemical activity in a synthetic carrier.